{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:17:12Z","timestamp":1788380232174,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objectives of this study were to build upon previously-reported 12-month findings by retrospectively comparing 24-month follow-up hospitalization charges and potentially-relevant readmissions in US lumbar fusion surgeries that employed either recombinant human bone morphogenetic protein-2 (rhBMP-2) or a cellular bone allograft comprised of viable lineage-committed bone cells (V-CBA) via a nationwide healthcare system database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 16,172 patients underwent lumbar fusion surgery using V-CBA or rhBMP-2 in the original study, of whom 3,792 patients (23.4%) were identified in the current study with all-cause readmissions during the 24-month follow-up period. Confounding baseline patient, procedure, and hospital characteristics found in the original study were used to adjust multivariate regression models comparing differences in 24-month follow-up hospitalization charges (in 2020 US dollars) and lengths of stay (LOS; in days) between the groups. Differences in potentially-relevant follow-up readmissions were also compared, and all analyses were repeated in the subset of patients who only received treatment at a single level of the spine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The adjusted cumulative mean 24-month follow-up hospitalization charges in the full cohort were significantly lower in the V-CBA group ($99,087) versus the rhBMP-2 group ($124,389; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), and this pattern remained in the single-level cohort (V-CBA\u2009=\u2009$104,906 vs rhBMP-2\u2009=\u2009$125,311; <jats:italic>P<\/jats:italic>\u2009=\u20090.0006). There were no differences between groups in adjusted cumulative mean LOS in either cohort. Differences in the rates of follow-up readmissions aligned with baseline comorbidities originally reported for the initial procedure. Subsequent lumbar fusion rates were significantly lower for V-CBA patients in the full cohort (10.12% vs 12.00%; <jats:italic>P<\/jats:italic>\u2009=\u20090.0002) and similar between groups in the single-level cohort, in spite of V-CBA patients having significantly higher rates of baseline comorbidities that could negatively impact clinical outcomes, including bony fusion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results of this study suggest that use of V-CBA for lumbar fusion surgeries performed in the US is associated with substantially lower 24-month follow-up hospitalization charges versus rhBMP-2, with both exhibiting similar rates of subsequent lumbar fusion procedures and potentially-relevant readmissions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13018-021-02829-0","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T10:03:14Z","timestamp":1637229794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-5542","authenticated-orcid":false,"given":"Bradley","family":"Wetzell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Dorsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"1","key":"2829_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/2192568217696688","volume":"8","author":"Z Buser","year":"2018","unstructured":"Buser Z, Ortega B, D\u2019Oro A, et al. Spine degenerative conditions and their treatments: national trends in the United States of America. Global Spine J. 2018;8(1):57\u201367.","journal-title":"Global Spine J"},{"issue":"9","key":"2829_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/BRS.0000000000002898","volume":"44","author":"NA Rosenthal","year":"2019","unstructured":"Rosenthal NA, Heinrich KH, Chung J, Yu H. Cost and hospital resource utilization of Staphylococcus aureus infection post elective posterior instrumented spinal fusion surgeries in US Hospitals: a retrospective cohort study. Spine (Phila Pa 1976). 2019;44(9):637.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"1","key":"2829_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5435\/00124635-200501000-00010","volume":"13","author":"SN Khan","year":"2005","unstructured":"Khan SN, Cammisa FP Jr, Sandhu HS, Diwan AD, Girardi FP, Lane JM. The biology of bone grafting. J Am Acad Orthop Surg. 2005;13(1):77\u201386.","journal-title":"J Am Acad Orthop Surg"},{"issue":"3","key":"2829_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00005131-198909000-00002","volume":"3","author":"EM Younger","year":"1989","unstructured":"Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma. 1989;3(3):192\u20135.","journal-title":"J Orthop Trauma"},{"issue":"6","key":"2829_CR5","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2021.3.FOCUS2152","volume":"50","author":"M McGrath","year":"2021","unstructured":"McGrath M, Feroze AH, Nistal D, Robinson E, Saigal R. Impact of surgeon rhBMP-2 cost awareness on complication rates and health system costs for spinal arthrodesis. Neurosurg Focus. 2021;50(6):E5.","journal-title":"Neurosurg Focus"},{"issue":"Suppl 5","key":"2829_CR6","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.4103\/2152-7806.114813","volume":"4","author":"NE Epstein","year":"2013","unstructured":"Epstein NE. Complications due to the use of BMP\/INFUSE in spine surgery: the evidence continues to mount. Surg Neurol Int. 2013;4(Suppl 5):S343.","journal-title":"Surg Neurol Int"},{"issue":"12","key":"2829_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.7326\/0003-4819-158-12-201306180-00006","volume":"158","author":"R Fu","year":"2013","unstructured":"Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158(12):890\u2013902.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2829_CR8","first-page":"E28","volume":"29","author":"MD Alvin","year":"2016","unstructured":"Alvin MD, Derakhshan A, Lubelski D, et al. Cost-utility analysis of 1-and 2-level dorsal lumbar fusions with and without recombinant human bone morphogenic protein-2 at 1-year follow-up. J Spinal Disord Tech. 2016;29(1):E28\u201333.","journal-title":"J Spinal Disord Tech"},{"issue":"14","key":"2829_CR9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/BRS.0000000000003442","volume":"45","author":"A Jain","year":"2020","unstructured":"Jain A, Yeramaneni S, Kebaish KM, et al. Cost-utility analysis of rhBMP-2 use in adult spinal deformity surgery. Spine (Phila Pa 1976). 2020;45(14):1009\u201315.","journal-title":"Spine (Phila Pa 1976)"},{"key":"2829_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s13018-020-02078-7","volume":"15","author":"B Wetzell","year":"2020","unstructured":"Wetzell B, McLean JB, Moore MA, Kondragunta V, Dorsch KA. A large database study of hospitalization charges and follow-up diagnoses in us lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2). J Orthop Surg Res. 2020;15:544.","journal-title":"J Orthop Surg Res"},{"issue":"3","key":"2829_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cpm.2018.02.002","volume":"35","author":"MK Magnus","year":"2018","unstructured":"Magnus MK, Iceman KL, Roukis TS. Living cryopreserved bone allograft as an adjunct for hindfoot arthrodesis. Clin Podiatr Med Surg. 2018;35(3):295\u2013310.","journal-title":"Clin Podiatr Med Surg"},{"issue":"1","key":"2829_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13018-019-1424-2","volume":"14","author":"JF Hall","year":"2019","unstructured":"Hall JF, McLean JB, Jones SM, Moore MA, Nicholson MD, Dorsch KA. Multilevel instrumented posterolateral lumbar spine fusion with an allogeneic cellular bone graft. J Orthop Surg Res. 2019;14(1):372.","journal-title":"J Orthop Surg Res"},{"key":"2829_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.22203\/eCM.v023a02","volume":"23","author":"E Birmingham","year":"2012","unstructured":"Birmingham E, Niebur G, McHugh PE. Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. Eur Cell Mater. 2012;23:13\u201327.","journal-title":"Eur Cell Mater"},{"issue":"32","key":"2829_CR14","doi-asserted-by":"publisher","first-page":"8150","DOI":"10.1016\/j.biomaterials.2011.07.041","volume":"32","author":"S Ghanaati","year":"2011","unstructured":"Ghanaati S, Unger RE, Webber MJ, et al. Scaffold vascularization in vivo driven by primary human osteoblasts in concert with host inflammatory cells. Biomaterials. 2011;32(32):8150\u201360.","journal-title":"Biomaterials"},{"issue":"10","key":"2829_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/term.392","volume":"5","author":"JC Reichert","year":"2011","unstructured":"Reichert JC, Quent VM, Noth U, Hutmacher DW. Ovine cortical osteoblasts outperform bone marrow cells in an ectopic bone assay. J Tissue Eng Regen Med. 2011;5(10):831\u201344.","journal-title":"J Tissue Eng Regen Med"},{"key":"2829_CR16","unstructured":"Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Office of Combination Products. Regulatory Considerations for Human, Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance for Industry and Food and Drug Administration Staff. In: US Department of Health and Human Services, Food and Drug Administration, eds. December ed2017."},{"key":"2829_CR17","unstructured":"Premier Healthcare Database: data that Informs and performs. 2018. https:\/\/products.premierinc.com\/downloads\/PremierHealthcareDatabaseWhitepaper.pdf. Accessed September 2018."},{"key":"2829_CR18","doi-asserted-by":"crossref","unstructured":"Dietz N, Sharma M, Kelly M, et al. Recombinant human bone morphogenetic protein-2 use in adult spinal deformity surgery: comparative analysis and healthcare utilization at 24 months\u2019 follow-up. Global Spine J. 2020.","DOI":"10.1177\/2192568220947377"},{"issue":"3","key":"2829_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.spinee.2007.03.004","volume":"8","author":"SD Glassman","year":"2008","unstructured":"Glassman SD, Carreon LY, Campbell MJ, et al. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. Spine J. 2008;8(3):443\u20138.","journal-title":"Spine J"},{"issue":"26","key":"2829_CR20","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1097\/BRS.0b013e318190705d","volume":"33","author":"SD Glassman","year":"2008","unstructured":"Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976). 2008;33(26):2843\u20139.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"6","key":"2829_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3171\/2018.12.SPINE18613","volume":"30","author":"MM Safaee","year":"2019","unstructured":"Safaee MM, Dalle Ore CL, Zygourakis CC, Deviren V, Ames CP. Estimating a price point for cost-benefit of bone morphogenetic protein in pseudarthrosis prevention for adult spinal deformity surgery. J Neurosurg Spine. 2019;30(6):814\u201321.","journal-title":"J Neurosurg Spine"},{"issue":"6","key":"2829_CR22","doi-asserted-by":"publisher","first-page":"e97049","DOI":"10.1371\/journal.pone.0097049","volume":"9","author":"H Zhang","year":"2014","unstructured":"Zhang H, Wang F, Ding L, et al. A meta analysis of lumbar spinal fusion surgery using bone morphogenetic proteins and autologous iliac crest bone graft. PLoS ONE. 2014;9(6):e97049.","journal-title":"PLoS ONE"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02829-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-021-02829-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02829-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T10:04:11Z","timestamp":1637229851000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-021-02829-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2829"],"URL":"https:\/\/doi.org\/10.1186\/s13018-021-02829-0","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient data for this study were considered deidentified in accordance with the HIPAA Privacy Rule described in Title 45 of the US Code of Federal Regulations (CFR) Part\u00a0164.506(d)(2)(ii)(B) and are exempt from Institutional Review Board oversight, as provided in 45 CFR 46.101(b)(4).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BW, JBM, MAM, and KD are employees of LifeNet Health\u00ae, the non-profit organization which funded the study. However, potential bias was minimized through a study design where real-world data were retrospectively obtained from a third-party database, which allows for evidence- and population-based analyses of drugs, devices, other treatments, disease states, epidemiology, resource utilization, healthcare economics, and clinical outcomes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"680"}}